# OnCo record idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine" ;
  schema:name "Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it"@en ;
  schema:alternateName "lineage plasticity surveillance prostate"@en, "TP53 RB1 loss monitoring prostate"@en, "pre-emptive platinum neuroendocrine prostate"@en ;
  schema:description "In a minority of men, prostate cancer escapes hormone drugs by becoming a different kind of cell that no longer needs the androgen receptor. By the time a biopsy shows it, the treatment options are almost gone. The genetic changes that allow the switch are detectable years earlier, and nobody is looking for them."@en ;
  schema:url <https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  onco:tag "prostate-evidence" ;
  onco:related <https://onco.cc/ideas/idea-bio1-cfrna-plasticity-tracking/>, <https://onco.cc/ideas/idea-bio1-ctc-derived-explants/>, <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/roadmaps/ctdna-tests/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-nepc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/neuroendocrine-differentiation/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-undruggable-targets/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/>, <https://onco.cc/key-papers/paper-aggarwal-t-sccpc-jco-2018/>, <https://onco.cc/key-papers/paper-rubin-mol-cell/>, <https://onco.cc/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/> .